MIFLASONE 400 micrograms, powder for inhalation in capsules 60 capsules
Active ingredients: BÉCLOMÉTASONE BASE, DIPROPIONATE DE BÉCLOMÉTHASONE
Commercialized according to BDPMDispensing in France: Prescription only
Powder for inhalation in capsules60 capsulesinhalée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- MIFLASONE 400 microgrammes, poudre pour inhalation en gélule
- Pharmaceutical form
- poudre pour inhalation en gélule
- Route of administration
- inhalée
- Presentation description
- plaquette(s) PVC-Aluminium PVDC avec inhalateur(s) de 60 gélule(s)
- Marketing authorisation holder
- NOVARTIS PHARMA
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 16 May 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67608173CIP73565955CIP133400935659552Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| DIPROPIONATE DE BÉCLOMÉTHASONEgélule | 400 microgrammes · une gélule | SA |
| BÉCLOMÉTASONE BASEgélule | 314 microgrammes · une gélule | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.